Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Enterprise Value to FCFF (EV/FCFF) 

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

Gilead Sciences Inc., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net income attributable to Gilead 8,510 480 5,665 4,592 6,225
Net loss attributable to noncontrolling interest (52) (26) (24)
Net noncash charges 5,457 11,228 4,696 6,269 4,694
Changes in operating assets and liabilities (3,948) (880) (2,303) (1,763) 489
Net cash provided by operating activities 10,019 10,828 8,006 9,072 11,384
Interest paid, net of amounts capitalized, net of tax1 900 661 729 712 733
Purchases of property, plant and equipment (563) (523) (585) (728) (579)
Free cash flow to the firm (FCFF) 10,356 10,966 8,150 9,056 11,538

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial information indicates a fluctuating pattern in both net cash provided by operating activities and free cash flow to the firm (FCFF) over the five-year period. While both metrics generally move in tandem, a closer examination reveals specific trends and potential areas of interest.

Overall Trend
Both net cash from operations and FCFF experienced a decline from 2021 to 2023, followed by a recovery in 2024 and 2025. The period between 2021 and 2023 demonstrates a contraction, while the subsequent two years show a return towards levels observed in 2021, though not a complete restoration.
Net Cash from Operating Activities
Net cash provided by operating activities decreased from US$11,384 million in 2021 to US$8,006 million in 2023, representing a reduction of approximately 29.5%. This decline suggests a potential weakening in the core business’s ability to generate cash from its primary operations. However, a substantial increase to US$10,828 million was observed in 2024, followed by a slight decrease to US$10,019 million in 2025. The 2024 increase indicates a potential turnaround or the impact of specific operational improvements.
Free Cash Flow to the Firm (FCFF)
FCFF mirrored the trend in operating cash flow, decreasing from US$11,538 million in 2021 to US$8,150 million in 2023, a decrease of approximately 29.3%. The FCFF also experienced a recovery in 2024, rising to US$10,966 million, and then slightly decreased to US$10,356 million in 2025. The close correlation between FCFF and operating cash flow suggests that changes in operating performance are a primary driver of FCFF fluctuations.
Relationship between Metrics
The difference between net cash from operating activities and FCFF is consistently minimal across all reported years. This suggests that capital expenditures, which are subtracted to arrive at FCFF, are relatively stable and do not significantly impact the overall free cash flow available to the firm. The consistent proximity of the two values indicates a predictable relationship between operational cash generation and cash available after necessary investments.

In summary, the period demonstrates a period of contraction followed by recovery in cash flow generation. The observed trends warrant further investigation into the underlying drivers of these fluctuations, including potential changes in revenue, cost structure, and capital expenditure policies.

AI Ask an analyst for more



Interest Paid, Net of Tax

Gilead Sciences Inc., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Effective Income Tax Rate (EITR)
EITR1 13.10% 30.50% 18.20% 21.50% 25.10%
Interest Paid, Net of Tax
Interest paid, net of amounts capitalized, before tax 1,036 951 891 907 979
Less: Interest paid, net of amounts capitalized, tax2 136 290 162 195 246
Interest paid, net of amounts capitalized, net of tax 900 661 729 712 733

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 2025 Calculation
Interest paid, net of amounts capitalized, tax = Interest paid, net of amounts capitalized × EITR
= 1,036 × 13.10% = 136


The analysis reveals fluctuations in both the effective income tax rate and interest expense, net of tax, over the five-year period. Interest expense, net of tax, demonstrates an overall increasing trend, while the effective income tax rate exhibits considerable volatility.

Interest Paid, Net of Tax
Interest paid, net of tax, remained relatively stable between 2021 and 2023, fluctuating around the $700 million mark. A decrease was observed in 2024, with the value falling to $661 million. However, a significant increase is noted in 2025, reaching $900 million. This represents the highest value within the observed period and suggests a potential rise in debt financing or changes in interest rates during that year.
Effective Income Tax Rate
The effective income tax rate experienced a notable decline from 25.10% in 2021 to 18.20% in 2023. A substantial increase occurred in 2024, rising to 30.50%. The rate then decreased significantly in 2025, falling to 13.10%. This volatility could be attributed to changes in tax legislation, geographic earnings mix, or the realization of tax benefits or liabilities.
Relationship between Interest Expense and Tax Rate
While not directly correlated, the increase in interest expense in 2025 coincides with a low effective income tax rate. This combination could indicate that the company is utilizing debt financing more extensively, potentially benefiting from lower tax liabilities. The increase in interest expense in 2025 is more pronounced than the fluctuations in the effective income tax rate, suggesting that the primary driver of the change in net interest expense is the expense itself, rather than tax effects.

Further investigation into the factors driving the changes in both the effective income tax rate and interest expense is recommended to provide a more comprehensive understanding of the company’s financial performance.

AI Ask an analyst for more



Enterprise Value to FCFF Ratio, Current

Gilead Sciences Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 170,876
Free cash flow to the firm (FCFF) 10,356
Valuation Ratio
EV/FCFF 16.50
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc. 22.53
Amgen Inc. 21.50
Bristol-Myers Squibb Co. 10.03
Danaher Corp. 24.97
Eli Lilly & Co. 112.85
Johnson & Johnson 27.09
Merck & Co. Inc. 23.43
Pfizer Inc. 17.17
Regeneron Pharmaceuticals Inc. 15.27
Thermo Fisher Scientific Inc. 25.80
Vertex Pharmaceuticals Inc. 33.74
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 27.71
EV/FCFF, Industry
Health Care 26.61

Based on: 10-K (reporting date: 2025-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.



Enterprise Value to FCFF Ratio, Historical

Gilead Sciences Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 200,502 158,992 109,266 122,947 97,096
Free cash flow to the firm (FCFF)2 10,356 10,966 8,150 9,056 11,538
Valuation Ratio
EV/FCFF3 19.36 14.50 13.41 13.58 8.42
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc. 23.29 20.05 14.89 12.15 13.18
Amgen Inc. 23.08 15.35 22.22 16.01 15.82
Bristol-Myers Squibb Co. 10.84 9.94 9.14 13.87 10.52
Danaher Corp. 29.01 28.93 36.34 25.74 28.25
Eli Lilly & Co. 107.04 200.96 655.43 59.17 38.39
Johnson & Johnson 28.52 18.16 19.30 23.80 21.25
Merck & Co. Inc. 25.30 13.24 37.84 19.09 23.27
Pfizer Inc. 18.08 15.33 32.24 9.15 8.40
Regeneron Pharmaceuticals Inc. 20.01 19.97 25.33 23.31 9.81
Thermo Fisher Scientific Inc. 28.42 26.13 28.85 31.61 33.14
Vertex Pharmaceuticals Inc. 36.94 29.45 16.68 22.47
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.89 23.59 27.29 18.08 16.12
EV/FCFF, Industry
Health Care 27.34 24.05 25.98 18.66 17.80

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 See details »

3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= 200,502 ÷ 10,356 = 19.36

4 Click competitor name to see calculations.


The Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) ratio exhibits an increasing trend over the observed period. Initial values indicate a ratio of 8.42 in 2021, which rises consistently through 2025, reaching 19.36.

Enterprise Value (EV)
Enterprise Value demonstrates volatility. It increased from US$97,096 million in 2021 to US$122,947 million in 2022, before decreasing to US$109,266 million in 2023. Subsequent increases are observed in 2024 and 2025, reaching US$158,992 million and US$200,502 million respectively.
Free Cash Flow to the Firm (FCFF)
Free Cash Flow to the Firm (FCFF) generally remains relatively stable, though with some fluctuation. A decrease is noted from US$11,538 million in 2021 to US$9,056 million in 2022, followed by a further decline to US$8,150 million in 2023. FCFF then recovers to US$10,966 million in 2024 and remains near this level at US$10,356 million in 2025.
EV/FCFF Ratio Trend
The increasing EV/FCFF ratio suggests that the enterprise value is growing at a faster rate than the free cash flow generated by the firm. The ratio nearly doubles from 2021 to 2025. This could indicate increasing investor expectations regarding future growth, a premium placed on the company’s assets, or potentially, a relative decline in the firm’s ability to generate cash flow compared to its valuation. The ratio’s increase is not solely attributable to changes in EV or FCFF, but rather a combination of both, with the EV increases outpacing the FCFF recovery.

The observed pattern warrants further investigation into the underlying drivers of both enterprise value and free cash flow to determine the sustainability of this trend and its implications for the firm’s valuation.

AI Ask an analyst for more